Analyzing New Drug Developments and Clinical Effectiveness in Targeted Cancer Therapies

Lata, Pandre, Maharana, Garg, Kaur and P

Health Leadership and Quality of Life, 2025, vol. 4, 606

Abstract: The quick progress in tailored cancer treatments has changed the field of oncology and opened up new ways to treat each patient individually. This essay looks at new drugs that have been made recently and how well they work in the real world. It focuses on focused therapies that try to stop certain molecular processes that are linked to cancer spreading. With the rise of precision medicine programs, it is important to understand how these treatments work, how well they work, and how safe they are in order to improve patient results. New focused treatments, like monoclonal antibodies, small molecule inhibitors, and CAR-T cell therapies, have shown potential in treating a number of cancers, such as breast, lung, and blood cancers. This study looks at the most important clinical trials that proved the effectiveness of the drugs that were approved in the last five years. One example is how the approval of osimertinib for EGFR-mutated non-small cell lung cancer (NSCLC) has made patients' chances of surviving and quality of life much better. In the same way, new drugs that target the BRAF and MEK pathways have changed the way cancer is treated. The study also looks at problems that come with tailored treatments, such as drug resistance, side effects, and the need for additional tests. Even though targeted treatments work, patients often develop secondary changes that make them resistant. To get around these problems, researchers are still working on combination therapies and new drugs. The study also stresses how important it is to find biomarkers that can help predict how well a treatment will work, which is necessary for making sure that each patient gets the best possible care. The study also talks about the economic effects of tailored treatments, comparing their high research costs to the chance of better patient results and lower total healthcare costs. As focused medicines keep getting better, it is very important for drug companies, governmental bodies, and healthcare workers to work together to make sure that everyone has equal access to these new treatments.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:health:v:4:y:2025:i::p:606:id:606

DOI: 10.56294/hl2025606

Access Statistics for this article

More articles in Health Leadership and Quality of Life from AG Editor
Bibliographic data for series maintained by Javier Gonzalez-Argote ().